LONDON – The European Investment Bank (EIB) is to put in €75 million (US$101.8 million) to directly fund six research programs at pharma company UCB SA, as part of a new "at-risk co-development funding" instrument under which the bank will invest €24 billion in R&D projects over the next seven years.